OPNT — Stock Film
STOCK FILMSCENE 1/11OPNT · $20.65
Stock Expert AI presents
OPNT
Opiant Pharmaceuticals, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Opiant Pharmaceuticals, Inc. A quick introduction.

On the stock market since 2007, it operates in the world of health and science. It has 37 employees. Now — the numbers.

on the stock market since 2007
37 employees
$108.8M market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, $7 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 7%

This is an established company with proven profits.

THE SALES TREND
Sales are growing overall, with a pause along the way.

Average growth of 22% a year over the last 4 years. Red columns mark years that ended in a loss.

$18.4M
2017
$13.5M
2018
$38.2M
2019
$27.4M
2020
$40.7M
2021
Cash on hand:
$0
Total debt:
$0
The cash outweighs the debt.

If every debt were paid off today, $35.8M would still be left in the vault — a solid cushion for hard times.

Every quarter, analysts set a profit bar.
How many of the last 8 did the company clear?
5 / 8
EXPECTATIONS MET OR BEATEN
5
May 2021
Aug 2021
Nov 2021
Mar 2022
May 2022
Aug 2022
Nov 2022
Mar 2023
5 TIMES IN THE LAST 8 QUARTERS
A mixed scorecard.
THE COUNCIL REVIEW
9

angles, checked one by one.

The 3 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Fat profit on each sale10/10
Heavy investment in the future10/10
WEAK SPOTS
The stock has lost its spark0/10
THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 44% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/2
Sales keep climbing

Over the last 3 years, sales grew about 44% a year on average.

2
THE BRIGHT SIDE · 2/2
Strong cash, light debt

There is $52.9M in the vault; even if every debt were paid off, $35.8M would remain.

1
THE RISKS · 1/2
A rich price tag

The company’s market value is 36 times its annual profit. Even a small disappointment could hit the price hard.

2
THE RISKS · 2/2
Executives lean toward selling

Over the last 12 months, executives reported 99 sells against just 29 buys. Not an alarm bell by itself, but a number worth watching.

FINALE · THE GRADE
C
0 / 100 · MoonshotScore

On our five-subject report card, OPNT sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.

The takeaway: OPNT is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film